Compagnie Lombard Odier SCmA Cuts Stake in IQVIA Holdings Inc. $IQV

Compagnie Lombard Odier SCmA lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 97,057 shares of the medical research company’s stock after selling 17,275 shares during the period. Compagnie Lombard Odier SCmA owned about 0.06% of IQVIA worth $18,435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Verdence Capital Advisors LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at about $3,612,000. Amundi raised its stake in IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares in the last quarter. Diversified Trust Co lifted its position in IQVIA by 57.2% during the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after purchasing an additional 15,487 shares during the last quarter. Nichols & Pratt Advisers LLP MA grew its stake in IQVIA by 8.6% in the 3rd quarter. Nichols & Pratt Advisers LLP MA now owns 122,603 shares of the medical research company’s stock worth $23,287,000 after buying an additional 9,684 shares in the last quarter. Finally, Act Two Investors LLC bought a new position in shares of IQVIA in the 2nd quarter worth $26,528,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the topic of a number of research analyst reports. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. TD Cowen increased their price objective on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Jefferies Financial Group decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday. BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday. Finally, Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $239.87.

IQVIA Stock Up 2.7%

Shares of NYSE:IQV opened at $192.58 on Tuesday. The stock’s 50-day moving average is $227.31 and its 200 day moving average is $209.81. The company has a market cap of $32.80 billion, a PE ratio of 24.50, a P/E/G ratio of 1.90 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.